Table 2. Clinical outcomes of 16 patients with myelofibrosis (MF) after initiation of sodium glucose co-transporter-2 inhibitors (SGLT-2I)

Outcomes after SGLT-2I therapy	
Increase in hemoglobin/hematocrit, *n (%)*	14 (88)
Peak hemoglobin g/dl, median (range)	12 (8-16)
- Male	12 (10-16)
- Female	11 (8-16)
Peak hematocrit %, median (range)	36 (24-50)
- Male	38 (32-48)
- Female	34 (24-50)
Change in hemoglobin/hematocrit	
- Change in hemoglobin g/dl, median (range)	1 (0-3)
- Change in hematocrit %, median (range)	4 (0-11)
- Time to peak hemoglobin/hematocrit in months, median (range)	6 (1-33)
Baseline leukocyte count x 10^9/l, median (range)	8 (5-22)
Leukocyte count at time of peak hemoglobin, x 10^9/l, median (range)	9 (8-24)
Baseline platelet count x 10^9/l, median (range)	361 (12-715)
Platelet count at time of peak hemoglobin, x 10^9/l, median (range)	386 (15-666)
Serum erythropoietin mIU/mL, median (range)	*n=7*
	52 (7-2448)
Pretreatment Serum erythropoietin mIU/mL, median (range)	*n*=3
Reference range (2.6 - 18.5 mIU/mL)	52 (26-55)
Serum ferritin mcg/L, median (range)	*n=16*
Reference range (24 - 336 mcg/L)	111 (20-3266)
Treatment for MF *n* (%)	
- Antiplatelet therapy	11 (69)
- Systemic Anticoagulation	7 (44)
- Cytoreductive therapy$^{\Omega}$	7 (44)
- Darbepoetin alfa	2 (13)
SGLT-2I treatment duration in months, median (range)	12 (2-73)
Thrombosis during SGLT-2I therapy, *n* (%)	
- Major arterial thrombosis, *n* (%)	0
- Major venous thrombosis, *n* (%)	2 (13)

$^{\Omega}$Cytoreductive therapy: Hydrea (n=2), Ruxolitinib (n=4), Momelotinib (n=1)

Figure Legend

Baseline hemoglobin, hemoglobin post-treatment and change in hemoglobin in 16 patients with myelofibrosis (MF) receiving sodium glucose co-transporter-2 inhibitors (SGLT-2I)

DA-α = Darbepoetin alfa

HU= Hydroxyurea

RUX= Ruxolitinib

MMB= Momelotinib


Baseline Hemoglobin
Post treatment Hemoglobin
Change in Hemoglobin
10.2
11
0.8
8.2
10.2
2
12.3
10.8
-1.5
9.4
10.4
1
10.9
13.1
2.2
14.4
15.1
0.7
14.7
16.1
1.4
10.3
11.9
1.6
8.7
11.6
2.9
10.8
11.5
0.7
9.9
11.9
2
10.7
11.1
0.4
9.2
10.2
1
7.9
8.2
0.3
13.7
15.9
2.2
11.3
11.4
0.1
PT1
PT2
PT3
PT4
PT5
PT6
PT7
PT8
PT9
PT10
PT11
PT12
PT13
PT14
PT15
PT16
DA-α
NONE
RUX
NONE
RUX
NONE
HU
RUX
RUX
NONE
DA-α
HU
NONE
MMB
NONE
NONE